Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMH4IVU)

Drug Name
Haloprogin Drug Info
Synonyms
Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
3561
ChEBI ID
CHEMBL1289
CAS Number
CAS 777-11-7
TTD Drug ID
D06ZAY

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
TNF signaling pathway 2.26 0.00e+0 103/112 (91.96%) NFKBIA;IL6;EDN1;...
Ferroptosis 2.20 0.00e+0 36/41 (87.8%) HMOX1;SLC7A11;SLC3A2;...
Prostate cancer 2.12 0.00e+0 93/97 (95.88%) CDKN1A;NFKBIA;FOXO1;...
IL-17 signaling pathway 2.11 0.00e+0 84/94 (89.36%) NFKBIA;S100A9;CXCL8;...
Toxoplasmosis 2.08 0.00e+0 103/112 (91.96%) HSPA6;NFKBIA;ALOX5;...
HIF-1 signaling pathway 2.03 0.00e+0 105/109 (96.33%) HMOX1;CDKN1A;IL6;...
Lipid and atherosclerosis 2.03 0.00e+0 190/215 (88.37%) HSPA6;NFKBIA;CXCL8;...
Fluid shear stress and atherosclerosis 2.01 0.00e+0 123/139 (88.49%) HMOX1;KLF2;CAV1;...
MicroRNAs in cancer 2.00 0.00e+0 146/310 (47.1%) HMOX1;DDIT4;CDKN1A;...
Small cell lung cancer 1.98 0.00e+0 90/92 (97.83%) CDKN1A;NFKBIA;MYC;...
MAPK signaling pathway 1.96 0.00e+0 272/294 (92.52%) HSPA6;RPS6KA2;MYC;...
Measles 1.95 9.34e-4 133/139 (95.68%) HSPA6;NFKBIA;IL6;...
Chronic myeloid leukemia 1.94 8.62e-4 72/76 (94.74%) CDKN1A;NFKBIA;MYC;...
Endometrial cancer 1.94 8.01e-4 56/58 (96.55%) CDKN1A;MYC;GADD45B;...
Leishmaniasis 1.90 7.47e-4 67/77 (87.01%) NFKBIA;TLR4;ITGB1;...
Non-small cell lung cancer 1.90 1.40e-3 70/72 (97.22%) CDKN1A;GADD45B;GADD45A;...
Rheumatoid arthritis 1.89 1.32e-3 78/93 (83.87%) CXCL8;IL6;TCIRG1;...
Focal adhesion 1.89 1.25e-3 180/201 (89.55%) CAV1;COMP;VWF;...
Legionellosis 1.88 1.77e-3 51/57 (89.47%) HSPA6;NFKBIA;CXCL8;...
Colorectal cancer 1.88 1.68e-3 84/86 (97.67%) CDKN1A;MYC;GADD45B;...
Malaria 1.87 1.60e-3 44/50 (88%) CXCL8;HBB;COMP;...
Hepatocellular carcinoma 1.87 1.53e-3 135/168 (80.36%) HMOX1;CDKN1A;MYC;...
Mitophagy 1.87 1.46e-3 56/68 (82.35%) SQSTM1;FOXO3;ATF4;...
AGE-RAGE signaling pathway in diabetic complications 1.84 3.74e-3 97/100 (97%) CXCL8;IL6;FOXO1;...
ErbB signaling pathway 1.83 4.48e-3 79/85 (92.94%) CDKN1A;MYC;NCK1;...
Ovarian steroidogenesis 1.83 4.74e-3 41/51 (80.39%) AKR1C3;CYP1B1;CYP1A1;...
Acute myeloid leukemia 1.82 4.98e-3 66/67 (98.51%) MYC;BAD;MAPK1;...
JAK-STAT signaling pathway 1.81 4.80e-3 146/162 (90.12%) CDKN1A;MYC;IL6;...
Autophagy 1.81 4.86e-3 113/169 (66.86%) DDIT4;SQSTM1;DAPK1;...
mTOR signaling pathway 1.80 4.70e-3 114/154 (74.03%) DDIT4;SLC3A2;RPS6KA2;...
Peroxisome -1.74 2.14e-2 72/82 (87.8%) SLC27A2;EHHADH;ACSL1;...
Cardiac muscle contraction -1.75 1.82e-2 64/87 (73.56%) SLC8A2;SLC9A6;COX6A2;...
Parkinson disease -1.79 1.14e-2 176/249 (70.68%) NDUFB11;MAPT;PSMA6;...
Butanoate metabolism -1.81 9.60e-3 23/28 (82.14%) BDH2;ACSM3;HADH;...
Diabetic cardiomyopathy -1.84 8.23e-3 162/203 (79.8%) NDUFB11;PARP1;NDUFS4;...
DNA replication -1.86 6.58e-3 34/36 (94.44%) RPA1;POLA2;RPA2;...
Valine, leucine and isoleucine degradation -1.87 7.31e-3 42/48 (87.5%) ACADSB;ACAA1;PCCB;...
Huntington disease -1.88 8.23e-3 233/306 (76.14%) POLR2A;POLR2F;CREB3;...
Fatty acid degradation -1.89 9.40e-3 40/43 (93.02%) CPT2;ALDH7A1;GCDH;...
Base excision repair -1.95 4.11e-3 29/33 (87.88%) POLL;POLB;APEX1;...
Retrograde endocannabinoid signaling -1.95 4.94e-3 118/148 (79.73%) NDUFB11;ABHD6;NDUFS4;...
Thermogenesis -1.99 0.00e+0 173/232 (74.57%) NDUFS6;SDHD;NDUFAF1;...
Ribosome -2.05 0.00e+0 113/158 (71.52%) RPS3;RPS14;RPLP1;...
Propanoate metabolism -2.09 0.00e+0 30/34 (88.24%) PCCB;LDHA;HIBCH;...
Oxidative phosphorylation -2.23 0.00e+0 93/133 (69.92%) NDUFB11;NDUFS4;ATP6V0E1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H